Daré Bioscience, Inc. (DARE) Stock Forecast
DARE analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $8.33 average of analyst targets
- Upside to target
- +1,049.4% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.09
- 52-week range
- $0.70 – $3.27
DARE analyst ratings
3 analystsNumber of analysts at each rating.
DARE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DARE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.27 | $0.10 | −$0.28 | +50.0% | 3 |
| Current fiscal year (2026) | −$0.77 | −$0.97 | −$0.43 | −$1.20 | +35.6% | 3 |
| Next fiscal year (2027) | −$0.41 | −$0.52 | −$0.31 | −$0.77 | +46.3% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DARE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.0M | $0 | $5.9M | +89,206.6% | 3 |
| Current fiscal year (2026) | $2.7M | $340,000 | $7.1M | +163.8% | 3 |
| Next fiscal year (2027) | $8.9M | $5.4M | $12.4M | +226.1% | 2 |
DARE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DARE revenue: reported and forecast
DARE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.16 | −$0.16 | −$0.16 | −$0.16 | −$0.14 | −12.5% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.95 | −$0.95 | −$0.95 | −$0.95 | −$0.77 | −18.3% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.52 | −$0.51 | −$0.51 | −$0.51 | −$0.41 | −20.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DARE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DARE beat in 9 of 12.
What analysts expect from DARE
3 analysts cover Daré Bioscience; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.33, 1,049.4% above the latest close of $0.72. Analysts expect earnings of −$0.77 per share for 2026, +35.6% from a year earlier. For 2027 the average estimate is −$0.41 per share on revenue of $8.9 million. Daré Bioscience beat the EPS estimate in 9 of the last 12 quarters.
Related: DARE income statement, DARE key metrics, DARE chart. See the DARE stock overview for the latest quote and news.
DARE forecast FAQ
What is Daré Bioscience's price target?
The average analyst price target for Daré Bioscience is $8.33, 1,049.4% above the latest close of $0.72.
Is Daré Bioscience a buy, hold or sell?
Of 3 analysts covering Daré Bioscience, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Daré Bioscience's EPS forecast?
Analysts forecast −$0.77 per share for 2026 (range −$0.97 to −$0.43); for 2027 the estimate is −$0.41.
What is Daré Bioscience's revenue forecast?
The average revenue estimate for 2026 is $2.7 million, growth of 163.8%; for 2027 it is $8.9 million.
When does Daré Bioscience report earnings?
Daré Bioscience is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.09.
Does Daré Bioscience usually beat earnings estimates?
Daré Bioscience reported EPS at or above the analyst estimate in 9 of the last 12 quarters.